MedPath

Effect of a Short Nap During the Night Shift of Healthcare Workers on Endothelial Function

Not Applicable
Recruiting
Conditions
Healthy Volonteers
Interventions
Behavioral: Control condition (30-min rest)
Behavioral: On-duty Nap
Device: EndoPAT
Device: Popmeter®
Device: Panasonic EW3109
Device: ECG Holter
Biological: Fasting blood sample
Other: Pichot fatigue scale
Other: French version of the Recovery Needs Scale (BRD)
Other: The Short-Form 36 (SF-36)
Other: Pittsburgh Sleep Quality Index (PSQI)
Other: Epworth questionnaire
Other: The Karolinska Sleepiness Scale
Device: Actimeter
Registration Number
NCT05955729
Lead Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Brief Summary

Night shift work is well known to cause health disruption in short and long term. It has been reported that among healthcare workers, nurses slept less than 6 h/24h. Consequences of such short sleep duration has been associated to long term issues such as endothelial dysfunction associated with cardiovascular diseases, arterial hypertension and type 2 diabetes. Countermeasures such as nap at work has potential effects on reducing the prevalence of cardiovascular diseases. However, to our knowledge, no studies have objectively investigated the effects of napping on endothelial function in a longitudinal design. Therefore, this study aims to investigate the effect of a 30 minutes on-duty nap during night work for 12 weeks on caregivers endothelial dysfunction.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
80
Inclusion Criteria
  • Being a paramedical caregiverr (nurse or care assistant) at Saint-Etienne University Hospital
  • Be aAged between 18 and 65
  • Working at least 80% of a full-time equivalent post
  • Working 12-hour shifts (day/night) in continuous care services
  • Being affiliated or entitled under a social security scheme
  • Havinge received informed information about the study and have co-signed, with the investigator, a consent to participate in the study
Exclusion Criteria
  • Have made a tTrans meridian journey in the last month prior to the study
  • Have a mMedically diagnosed sleep disorder such asof the hypersomnia or insomnia type
  • Have a diagnosed and treated mental pathology
  • Usually take a nap in the workplace in a quiet room
  • Be pregnant or breastfeeding
  • Have medically diagnosed neurovascular or neuromuscular pathologies

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Nap groupEndoPATThe experimental group will be allocated to do a 30-min on-duty nap during night work, in a dedicated room between 1 am and 4 am.
Nap groupPanasonic EW3109The experimental group will be allocated to do a 30-min on-duty nap during night work, in a dedicated room between 1 am and 4 am.
Nap groupFasting blood sampleThe experimental group will be allocated to do a 30-min on-duty nap during night work, in a dedicated room between 1 am and 4 am.
Nap groupFrench version of the Recovery Needs Scale (BRD)The experimental group will be allocated to do a 30-min on-duty nap during night work, in a dedicated room between 1 am and 4 am.
Control groupPopmeter®The control group will be allocated to rest in a dedicated room without napping between 1 am and 4 am.
Nap groupEpworth questionnaireThe experimental group will be allocated to do a 30-min on-duty nap during night work, in a dedicated room between 1 am and 4 am.
Nap groupThe Karolinska Sleepiness ScaleThe experimental group will be allocated to do a 30-min on-duty nap during night work, in a dedicated room between 1 am and 4 am.
Control groupControl condition (30-min rest)The control group will be allocated to rest in a dedicated room without napping between 1 am and 4 am.
Control groupEndoPATThe control group will be allocated to rest in a dedicated room without napping between 1 am and 4 am.
Control groupPanasonic EW3109The control group will be allocated to rest in a dedicated room without napping between 1 am and 4 am.
Control groupFasting blood sampleThe control group will be allocated to rest in a dedicated room without napping between 1 am and 4 am.
Control groupPichot fatigue scaleThe control group will be allocated to rest in a dedicated room without napping between 1 am and 4 am.
Control groupThe Short-Form 36 (SF-36)The control group will be allocated to rest in a dedicated room without napping between 1 am and 4 am.
Control groupFrench version of the Recovery Needs Scale (BRD)The control group will be allocated to rest in a dedicated room without napping between 1 am and 4 am.
Nap groupPopmeter®The experimental group will be allocated to do a 30-min on-duty nap during night work, in a dedicated room between 1 am and 4 am.
Nap groupPittsburgh Sleep Quality Index (PSQI)The experimental group will be allocated to do a 30-min on-duty nap during night work, in a dedicated room between 1 am and 4 am.
Nap groupOn-duty NapThe experimental group will be allocated to do a 30-min on-duty nap during night work, in a dedicated room between 1 am and 4 am.
Nap groupPichot fatigue scaleThe experimental group will be allocated to do a 30-min on-duty nap during night work, in a dedicated room between 1 am and 4 am.
Control groupPittsburgh Sleep Quality Index (PSQI)The control group will be allocated to rest in a dedicated room without napping between 1 am and 4 am.
Control groupECG HolterThe control group will be allocated to rest in a dedicated room without napping between 1 am and 4 am.
Nap groupECG HolterThe experimental group will be allocated to do a 30-min on-duty nap during night work, in a dedicated room between 1 am and 4 am.
Nap groupThe Short-Form 36 (SF-36)The experimental group will be allocated to do a 30-min on-duty nap during night work, in a dedicated room between 1 am and 4 am.
Nap groupActimeterThe experimental group will be allocated to do a 30-min on-duty nap during night work, in a dedicated room between 1 am and 4 am.
Control groupEpworth questionnaireThe control group will be allocated to rest in a dedicated room without napping between 1 am and 4 am.
Control groupThe Karolinska Sleepiness ScaleThe control group will be allocated to rest in a dedicated room without napping between 1 am and 4 am.
Control groupActimeterThe control group will be allocated to rest in a dedicated room without napping between 1 am and 4 am.
Primary Outcome Measures
NameTimeMethod
Evolution of reactive hyperemia index (RHI)Change between week 1 and 12

RHI is measured through the EndoPAT device® initially and at 12 weeks, and corresponds to the vascular reactivity following a 5-min occlusion on an arm

Secondary Outcome Measures
NameTimeMethod
Evolution of pro-inflammatory biomarkersChange between week 1 and 12

Fasting blood sample to measure hsCRP, IL-6 TNF-α, IL-1β initially and at 12 weeks.

Evolution of alertness at work assessedChange between week 1 and 12

The Karolinska Sleepiness Scale measures daytime sleepiness on a 9-point scale, based on 5 states and 4 intermediate states that are not verbally indicated, initially and at 12 weeks.

Evolution of sleep timeChange between week 1 and 12

Actimeter measuring variations in wake-up and bedtimes, sleep duration, energy expenditure and time spent at different levels of physical activity intensity (sedentary, light intensity, moderate to intense intensity), initially and at 12 weeks.

Evolution of sleep durationChange between week 1 and 12

Actimeter measuring variations in wake-up and bedtimes, sleep duration, energy expenditure and time spent at different levels of physical activity intensity (sedentary, light intensity, moderate to intense intensity), initially and at 12 weeks.

Evolution of pulse wave velocity (PWV)Change between week 1 and 12

PWV is measured through the Popmeter® initially and at 12 weeks, and corresponds to the finger-o-foot pulse wave velocity(m/s)

Evolution of blood markers of endothelial functionChange between week 1 and 12

Fasting blood sample to measure NO, SOD, IL-18 initially and at 12 weeks.

Evolution of subjective FatigueChange between week 1 and 12

The Pichot fatigue scale (composed of 8 items, a score above 22 indicates excessive fatigue), initially and at 12 weeks.

Evolution of recovery NeedsChange between week 1 and 12

French version of the Recovery Needs Scale (BRD), initially and at 12 weeks, wich consists of 11 items coded 0 or 1. A score is calculated for each participant, multiplied by 10 to give a score ranging from 0 to 100. The greater the need for recovery, the higher the score.

Evolution of subjective sleepinessChange between week 1 and 12

Epworth questionnaire, initially and at 12 weeks : 8-question sleepiness assessment scale, a score above 10 indicates excessive sleepiness

Evolution of blood pressureChange between week 1 and 12

Systolic and diastolic blood pressure (mm Hg) measured in the sitting position in triplicate with an automatic blood pressure device (Panasonic EW3109) on the left arm, initially and at 12 weeks.

Evolution of heart rate variability (HRV)Change between week 1 and 12

24-h Holter-Electrocardiogram to derive temporal (SDNN, rMSSD, pNN50) and frequency (LF, HF, LF/HF) HRV indices initially and at 12 weeks.

Evolution of state of healthChange between week 1 and 12

The SF-36 questionnaire is used to assess quality of life, initially and at 12 weeks. It comprises 8 sub-scores ranging from 0 (minimum quality of life) to 100 (maximum well-being).

Evolution of sleep qualityChange between week 1 and 12

Pittsburgh Sleep Quality Index (PSQI), initially and at 12 weeks : 24-question sleep quality assessment scale, a score \> 5 indicates poor sleep quality.

Trial Locations

Locations (1)

Chu de Saint-Etienne

🇫🇷

Saint-Étienne, France

© Copyright 2025. All Rights Reserved by MedPath